Risk of systemic adverse events similar after bevacizumab, ranibizumab, aflibercept
The risk of acute myocardial infarction (MI), cardiovascular disease (CVD), major bleeding, or all-cause hospitalization is comparable following treatment with intravitreal bevacizumab, ranibizumab, and aflibercept during routine clinical practice, a retrospective cohort study has shown.